"ASCO 2019: Randomized Double-blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-line Chemotherapy in Patients with Metastatic Urothelial Cancer: HCRN GU14-182"
Although anti-PD-1/L1 checkpoint blockade has made substantial inroads into the treatment landscape of metastatic urothelial cancer, platinum-based chemotherapy constitutes the current standard of care in the first-line setting, according to a new study by researchers at the Icahn School of Medicine at Mount Sinai. Matthew Galsky, MD, director of genitourinary medical oncology at The Tisch Cancer Institute at Mount Sinai lead the studyand reported patients with at least stable disease following no more than eight cycles of platinum-based chemotherapy stratified patients by lymph-node only metastases as well as by response to platinum and randomized to pembrolizumab or to placebo. Dr. Galsky explained that while switch-maintenance pembrolizumab significantly improves progression-free survival, overall survival data are not yet matured and will be presented in the future.
— Matthew D. Galsky, MD, Director of Genitourinary Medical Oncology at The Tisch Cancer Institute at Mount Sinai